Full text is available at the source.
Abstract
Finerenone may reduce cardiovascular, kidney, and metabolic risks in individuals with type 2 diabetes and chronic kidney disease.
- The study focuses on the effects of finerenone combined with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA).
- Outcomes assessed include changes in estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) over a period of six months.
- Limited evidence exists regarding the safety and effectiveness of this combination therapy in routine care for adults with type 2 diabetes-related chronic kidney disease.
Simplified